Breast Coil Market Size, Share, and Growth Forecast 2026 - 2033

The global breast coil market size is likely to be valued at US$355.4 million in 2026 and is estimated to reach US$820.6 million by 2033, growing at a CAGR of 12.7% during the forecast period from 2026 to 2033, driven by the rising global burden of breast cancer, expanding breast MRI screening infrastructure, and surging preference for high-channel phased-array coils that improve diagnostic clarity and comfort. Wide breast density notification requirements are also increasing the pool of women referred for MRI-based breast evaluation.

Driver- Rising Breast Cancer Burden to Widen the Pool of MRI Candidates

Breast cancer remains the most diagnosed cancer among women worldwide, and its growing incidence is expanding the population eligible for supplemental MRI evaluation. The American Cancer Society estimates about 321,910 new invasive breast cancer cases and 60,730 cases of ductal carcinoma in situ among U.S. women in 2026, alongside roughly 42,140 deaths. This large patient base continues to support demand for dedicated breast coils.

The disease burden is even larger globally. The World Health Organization (WHO) estimated about 2.3 million new breast cancer cases and 666,000 deaths worldwide in 2022, projected to rise more than 50% by 2050 as populations grow and age. As emerging economies expand cancer screening infrastructure, demand for breast MRI capacity, and the coils that support it, is expected to rise.

National Screening Mandates to Lift Referral Volumes for Breast MRI

Regulatory changes are widening access to supplemental breast imaging. Since September 2024, the FDA's national breast density notification standard under the Mammography Quality Standards Act has required U.S. mammography facilities to inform patients of dense breast tissue and note that supplemental screening, including MRI, may help detect cancers mammography can miss. This uniform standard replaced a patchwork of state laws and is raising patient awareness.

Insurance access is following suit. Effective January 1, 2026, new federal guidelines from the Health Resources and Services Administration expanded insurance coverage for supplemental breast imaging under most Affordable Care Act-qualified plans for average-risk women. As financial barriers ease alongside greater awareness, referral volumes for breast MRI are expected to climb, supporting continued investment in coil hardware.

Restraint- High Exam Costs and Narrow Reimbursement May Limit Broad Adoption

Cost remains a meaningful barrier to expanding breast MRI beyond high-risk populations. A breast MRI exam can cost five to 10 times more than a screening mammogram, and research in the Journal of the National Cancer Institute found out-of-pocket charges can be substantial for women without comprehensive coverage, particularly those on high-deductible plans. This limits the pace at which smaller centers upgrade breast coil hardware.

Clinical guidance also narrows the addressable population. The American College of Radiology primarily recommends annual screening MRI for women with a 20% or greater lifetime risk of breast cancer, rather than as a routine tool for average-risk women. As MRI utilization remains low even where coverage exists, smaller and mid-sized centers may be slower to justify the capital expense of new coil systems.

Opportunity- Wearable and Flexible Coil Designs to Improve Patient Comfort

Researchers are exploring flexible, wearable alternatives to rigid breast coil hardware to improve comfort and workflow. A team at the Medical University of Vienna described a vest-like receive-only coil array, worn similarly to a sports bra, in a 2023 study in Investigative Radiology. The design accommodates a wide range of breast sizes and supports both supine and prone imaging without repositioning.

Follow-up research in the European Journal of Radiology in 2025 examined how supine imaging with a wearable coil could translate more easily into surgical planning, since supine positioning matches how patients are positioned during surgery. As such designs mature, manufacturers have an opportunity to differentiate offerings around comfort, faster setup, and closer alignment with treatment planning.

Low-Field and AI-Integrated Coils to Expand the Installed Base

Coil manufacturers are extending breast imaging support to lower-field MRI systems, which cost less to install and operate than 1.5T or 3.0T scanners. In April 2026, the FDA cleared NeoCoil's 0.55T 12-Channel Breast Coil, opening dedicated breast MRI capability to lower-cost scanners and widening access at facilities that could not previously justify a high-field program.

At the higher end of the market, manufacturers are pairing high-channel coil architecture with AI-assisted image reconstruction. Siemens Healthcare, for instance, offers a 16-channel AI-enabled breast coil built for high-resolution 2D and 3D breast MRI, using integrated preamplifiers for faster parallel imaging. As such tools mature, manufacturers have an opportunity to bundle hardware with software-driven gains in throughput and image consistency.

Design Type Insights

Closed/prone bilateral coils are predicted to lead with a share of about 57.8% in 2026, as their fully enclosed, dual-breast architecture delivers consistent signal-to-noise ratio and stable positioning for both screening and MRI-guided biopsies. Hospitals favor this configuration for high patient throughput, since both breasts can be imaged in a single acquisition, and the enclosed design limits motion artifacts during longer sequences.

Unilateral and open-access coils are estimated to grow at a comparatively faster pace over the forecast period, as they offer easier lateral and medial access for procedures such as MRI-guided wire localization and vacuum-assisted biopsy. These designs suit patients who cannot tolerate prolonged prone positioning, and their smaller footprint makes them attractive for outpatient breast care and specialty biopsy suites.

Application Insights

Screening & diagnosis is anticipated to dominate with a share of around 61.3% in 2026, supported by expanding use of supplemental MRI for women with dense breast tissue or an elevated lifetime risk of breast cancer. The American College of Radiology Imaging Network trial and subsequent studies have shown MRI detects cancers not visible on mammography, reinforcing its role as a complement to routine mammographic screening.

Biopsy & interventional guidance is expected to remain an important secondary application, as suspicious findings on screening MRI often require MRI-guided localization or vacuum-assisted biopsy for confirmation. Preoperative planning and treatment-response monitoring are also gaining traction, particularly for patients on neoadjuvant chemotherapy, where serial breast MRI helps clinicians track tumor response before surgery.

North America Breast Coil Market Trends

North America is predicted to dominate globally in 2026 with a share of approximately 42.5%, supported by well-established breast imaging infrastructure, high MRI scanner density, and the FDA's national breast density notification standard, which has raised awareness of supplemental screening options. The region also benefits from a concentrated base of coil manufacturers and strong reimbursement pathways for high-risk screening populations, supporting steady equipment upgrades across hospitals and imaging centers.

U.S. Breast Coil Market Trends

A share of nearly 88.6% is expected to be held by the U.S. in North America in 2026, as it combines a large screening-eligible population, the highest concentration of breast MRI-capable scanners, and expanding federal insurance coverage under guidelines that took effect in January 2026. Ongoing replacement of aging coil hardware at academic medical centers is further supporting demand across the country.

Asia Pacific Breast Coil Market Trends

Asia Pacific is anticipated to be the fastest-growing region globally in 2026 with a share of around 24.1%, supported by expanding diagnostic imaging infrastructure, rising breast cancer incidence, and growing government-backed screening programs. Demand is not concentrated in a single country, with China, Japan, South Korea, and India each contributing meaningfully to regional coil installations as hospitals modernize imaging fleets.

China Breast Coil Market Trends

China will likely lead Asia Pacific in 2026 with a share of about 33.6%, as its expanding hospital network and rising urban breast cancer awareness are driving investment in dedicated breast imaging equipment. Regulatory modernization is also playing a role; China's National Healthcare Security Administration issued a national guideline in June 2025 covering more than 100 diagnostic and imaging-related service items, supporting standardized pricing and broader access.

India Breast Coil Market Trends

India is projected to account for a share of about 18.9% in Asia Pacific in 2026, as expanding private healthcare infrastructure and rising MRI installations are widening access to breast imaging outside major metros. In February 2026, Wipro GE Healthcare launched its SIGNA Prime Elite MR imaging system in Hyderabad, part of a broader push to expand India's domestically manufactured MRI capacity and the installed base eligible for breast coil upgrades.

Europe Breast Coil Market Trends

Europe will likely register steady growth over the forecast period with a share of roughly 21.8% in 2026 globally, supported by mature breast imaging infrastructure, established radiology training, and growing use of MRI as a supplemental tool for women with dense breasts or hereditary risk factors. The European Society of Breast Imaging's guidance favoring annual MRI for high-risk women continues to support steady coil demand across specialist breast centers.

Germany Breast Coil Market Trends

Germany is predicted to register a substantial share of approximately 27.4% in 2026 within Europe, supported by a large base of radiology specialists, strong medical device manufacturing infrastructure, and high healthcare quality standards favoring advanced, high-channel coil systems. Patients and physicians in the country place considerable weight on image quality and diagnostic confidence, favoring established, well-validated coil platforms over lower-cost alternatives.

U.K. Breast Coil Market Trends

A share of nearly 19.6% is predicted to be held by the U.K. within Europe in 2026, as the National Health Service continues to expand access to MRI for women at higher hereditary or familial risk of breast cancer. Growing use of abbreviated MRI protocols, which shorten scan times while preserving diagnostic accuracy, is helping departments manage patient throughput without proportional increases in scanner capacity.

The global breast coil market is moderately consolidated, with a small group of established medical imaging companies accounting for the majority of installed coil systems worldwide. Leading MRI system manufacturers compete by bundling proprietary, high-channel breast coils with their scanner platforms, while independent coil specialists compete on compatibility, patient comfort, and biopsy-access features retrofitted onto existing scanner fleets. This gives hospitals a choice fbetween OEM-bundled coils and independent aftermarket options when upgrading capacity.

Competitive intensity is increasingly centered on channel count, AI-assisted image reconstruction, and comfort features such as adjustable padding and reduced setup time. Manufacturers also differentiate through compatibility across multiple scanner platforms and field strengths, since centers with mixed fleets prefer coils that avoid vendor lock-in. As volumes grow, competition is expected to intensify around faster protocols and closer integration with AI-based interpretation software.

Key Industry Developments:

• In April 2026, the FDA cleared NeoCoil's 0.55T 12-Channel Breast Coil, extending dedicated breast imaging support to lower-field MRI systems and broadening the scanner base able to support breast MRI programs.
• In April 2026, GE HealthCare expanded its partnership with DeepHealth, a RadNet subsidiary, to accelerate global adoption of breast cancer screening solutions, including workflow efficiency gains and second-reader AI capabilities.
• In February 2026, Wipro GE Healthcare launched the SIGNA Prime Elite MR imaging system at IRIA 2026 in Hyderabad, expanding its domestically manufactured MRI portfolio and the installed base available for breast imaging upgrades in India.